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The modulating effect of N-acetylcysteine (NAC) on the activity of different antibiotics has been studied in Pseudomonas aerugi-
nosa. Our results demonstrate that, in contrast to previous reports, only the activity of imipenem is clearly affected by NAC. MIC
and checkerboard determinations indicate that the NAC-based modulation of imipenem activity is dependent mainly on OprD.
SDS-PAGE of outer membrane proteins (OMPs) after NAC treatments demonstrates that NAC does not modify the expression
of OprD, suggesting that NAC competitively inhibits the uptake of imipenem through OprD. Similar effects on imipenem activ-
ity were obtained with P. aeruginosa clinical isolates. Our results indicate that imipenem-susceptible P. aeruginosa strains be-
come resistant upon simultaneous treatment with NAC and imipenem. Moreover, the generality of the observed effects of NAC
on antibiotic activity was assessed with two additional bacterial species, Escherichia coli and Acinetobacter baumannii. Caution
should be taken during treatments, as the activity of imipenem may be modified by physiologically attainable concentrations of
NAC, particularly during intravenous and nebulized regimes.
Although its benefit has been questioned (1), N-acetylcysteine(NAC) is being used for the treatment of numerous disorders,
including paracetamol intoxication, doxorubicin cardiotoxicity,
ischemia-reperfusion cardiac injury, acute respiratory distress
syndrome, bronchitis, chemotherapy-induced toxicity, HIV/
AIDS, heavy metal toxicity, and psychiatric disorders (2). This
compound is also sold as a dietary supplement, with claims of
antioxidant and liver-protecting effects. The antioxidant activity
of NAC has been attributed to its reactivity with ·OH, ·NO2,
CO3·
, and thiyl radicals, to its capacity for repair of oxidized key
cellular molecules, and to its activity as a precursor for glutathione
biosynthesis (2). Because of this mucolytic capacity, it has also
been used to facilitate the processing of sputum specimens in bac-
teriology laboratories (3). The ability of NAC to reduce biofilms,
alone or in combination with antimicrobials, has been addressed
in several bacterial species (4–6). Furthermore, NAC has been
proposed as a treatment in Helicobacter pylori infections (7). NAC
utility in reducing sputum viscosity in patients with cystic fibrosis
(CF) and chronic obstructive pulmonary disease (COPD) (8),
likely due to its ability to break disulfide bonds, has also been
claimed, although its mechanism of action is not well understood.
As a result of an imbalance between the production of reactive
oxygen species (ROS) caused by inflammation and their inactiva-
tion by the impaired antioxidant systems, CF patients with
chronic Pseudomonas aeruginosa lung infection have increased
oxidative stress. Therefore, antioxidant interventions, including
the use of NAC, have been proposed to reduce the extent of oxi-
dative lesions and the rate of lung deterioration (for a review, see
reference 9). However, although controversial results on the im-
provement of lung function have been obtained in clinical trials
(9–11), NAC is still being considered positively by many clinicians
for the treatment of CF patients.
It has recently been shown that NAC is an important modula-
tor of antibiotic activity, reducing the antibacterial activity of ami-
noglycosides, fluoroquinolones, and erythromycin and enhanc-
ing that of ampicillin, with little or no effect on the activity of
chloramphenicol, tetracycline, and penicillin, on different bacte-
rial species, including P. aeruginosa (12). Also, an older study (13)
reported that P. aeruginosa strains were inhibited synergistically
by NAC and carbenicillin or ticarcillin and that NAC antagonized
the activity of gentamicin and tobramycin. Interestingly, in that
study low concentrations of NAC showed a growth-inhibitory
effect on P. aeruginosa (13). Nevertheless, the effect of NAC on the
activity of most antipseudomonal drugs has not been addressed.
Since NAC is so widely used, knowledge of the putative effects
of NAC on antibiotic activity on P. aeruginosa is of capital impor-
tance. Therefore, we decided to evaluate the effect of NAC on the
activity of different antipseudomonal drugs, including imipenem
(IMI), meropenem, aztreonam, ceftazidime, ciprofloxacin, tobra-
mycin, and colistin, on P. aeruginosa. Interestingly, only imi-
penem activity was clearly affected by NAC. Consequently, the
molecular basis of this phenomenon and its generality in other P.
aeruginosa clinical isolates have been studied. Furthermore, we
tested the generality of the NAC modulating effect on other bac-
terial species such as Escherichia coli and Acinetobacter baumannii.
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MATERIALS AND METHODS
Bacterial strains and media. P. aeruginosa strains PAO1 and PAOD1
(14), PA14 and FQSE21-1003 (15), and Pamb18 and Pamb91 (16), E. coli
K-12 strain BW25113 (17), and A. baumannii strain ATCC 17978 were
used in this study. A pharmaceutical preparation of NAC (Hidonac 100;
Zambon, Barcelona, Spain), containing NAC (100 mg/ml), disodium
edetate (3 mg/ml) as a preservative, and sodium hydroxide (pH 6.5), was
used. This formulation is very similar to other preparations dispensed
elsewhere (e.g., Mucomyst in the United States). Pure NAC powder was
purchased from Sigma-Aldrich as N-acetyl-L-cysteine, Sigma grade
99% (TLC), and dissolved in sterilized double-distilled water. The pH
was adjusted with sodium hydroxide when indicated. Antibiotic and NAC
solutions were made fresh daily, filtered through a sterile 0.22-m mem-
brane filter, and used within 12 h of preparation.
Growth with NAC. Exponential cultures of P. aeruginosa strains were
diluted 1:1,000 in Mueller-Hinton broth (MHB) and grown in 96-well
plates (Nunclon delta surface; Thermo Scientific). When appropriate,
MHB was supplemented with NAC. Plates were incubated at 37°C with
regular orbital shaking in a microplate reader (Infinite F200; Tecan, Swit-
zerland). Absorbance at 595 nm was recorded in at least 6 biological rep-
licates.
MIC estimation. MICs of different antibiotics and NAC were deter-
mined in MHB as outlined by the Clinical and Laboratory Standards
Institute (CLSI) (18). The effect of NAC on bacterial susceptibility to
different antibiotics was studied by adding NAC to the broth. A concen-
tration of 10 mM NAC (equivalent to 1.6 mg/ml or 0.16%) was used to
match that in a previous study on NAC-based modulation of antibiotic
susceptibility (12). For experiments involving preincubation with NAC,
exponentially growing cultures of PAO1 and PAOD1 were incubated with
10 mM NAC for 2.5 h. NAC was eliminated by saline washing, and
MICs of imipenem were determined as indicated above. Interactions
between NAC and imipenem were studied by the use of the checker-
board method and analyzed according to EUCAST recommendations
(19).
OMP analysis. Cultures of P. aeruginosa were grown overnight at 37°C
in 5 ml of MHB medium and then diluted 100-fold into fresh medium.
Bacterial cells were incubated with different N-acetylcysteine (Hidonac)
concentrations (0 mg/ml, 0.8 mg/ml, and 1.6 mg/ml) for 4 h with shaking
at 37°C. Outer membrane proteins (OMPs) were obtained using a previ-
ously reported method (20), OMPs were then separated by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained
with Coomassie blue. OprD profiles of PAO1 and the PAO1 oprD mutant
with and without NAC were compared.
RESULTS AND DISCUSSION
Effect of NAC on growth of P. aeruginosa. Because low concen-
trations of NAC were previously shown to be inhibitory for the
growth of P. aeruginosa (13), we first tested the effect of 10 mM
NAC (Hidonac), a concentration that match that in the previous
study on NAC-based modulation of antibiotic susceptibility (12),
on the growth of several strains of P. aeruginosa. According to that
report (12), this concentration can be reached in patients with
severe respiratory disorders treated with high doses of NAC.
Moreover, it has been proposed that the concentration of active
NAC in the lower airways after its administration via nebulization
of a single dose of 300 mg may be as high as 29 mM (21). There-
fore, 10 mM is a realistic concentration of NAC to be tested. Figure
1 shows that after 16 h of growth, this concentration of NAC
produced little or no effect on the growth of the tested strains, a
result that does not fit with those previously published (13).
pH is the key parameter in the NAC effect on the activity of
antibiotics in P. aeruginosa PAO1, except on that of imipenem.
Our data demonstrate that the addition of a 10 mM concentration
of the pharmaceutical preparation of NAC (Hidonac) had little or
no effect on P. aeruginosa PAO1 susceptibility (Table 1, MH and
NAC-P), except in the case of imipenem (see below). As stated in
Materials and Methods, the pharmaceutical formulation con-
tained, in addition to NAC (100 mg/ml), disodium edetate (3
mg/ml) and sodium hydroxide (pH 6.5). This formulation is very
similar to other preparations dispensed elsewhere (e.g., Muco-
myst in the United States). Therefore, the NAC-mediated modi-
fication of MICs observed by others (12) could be due to the ab-
sence of these additional compounds.
To test this possibility, pure NAC powder purchased from
Sigma was dissolved in sterilized double-distilled water and used
to measure its effect on the susceptibility of P. aeruginosa to the
antibiotics described above. Table 1 shows that this NAC prepa-
ration (NAC-) decreased the activity of most antibiotics against
P. aeruginosa PAO1. The activities of ciprofloxacin, tobramycin,
and imipenem were the most affected. Finally, the activities of
ceftazidime, aztreonam, meropenem, and colistin were slightly
changed or not modified.
To study the importance of the other compounds present in
the pharmaceutical formulation of NAC for the antibiotic activity,
a simulated pharmaceutical formulation was prepared with the
NAC powder purchased from Sigma. NAC (100 mg/ml) and di-
sodium edetate (Sigma) (3 mg/ml) were dissolved in sterilized
double-distilled water. Sodium hydroxide was added to adjust the
pH to 6.5. As shown in Table 1 (NAC--pH), the MICs of the
tested antibiotics, except imipenem, showed levels similar to those
reached without NAC or with the pharmaceutical formulation.
When the NAC powder from Sigma was dissolved in sterilized
double-distilled water, the pH of the NAC solution was equal to
1.8, far below that of the pharmaceutical preparation (pH 6.5).
When the pH of this NAC solution was adjusted to 6.5 with so-
dium hydroxide, its addition to Mueller-Hinton broth did not
modify the final pH of the broth (pH 7.3); i.e., the pH of the
Mueller-Hinton broth containing NAC is close to neutrality (Ta-
ble 1) in all cases, except for that containing the pure NAC powder
dissolved in water without pH adjustment (final pH 5.7). of Table
1 (NAC--pH and NAC--EDTA-pH) shows that the activity of
antibiotics, previously modified by the solution of NAC powder,
was almost completely recovered when the pH of this NAC prep-
aration was adjusted to 6.5.
Again, our results do not match those previously published by
others (12, 13), as NAC, under our experimental conditions, does
not modify the activity of most antibiotics tested against P. aerugi-
FIG 1 Effect of 10 mM NAC on P. aeruginosa growth. For the six strains tested,
absorbance at 595 nm was measured after 16 h of growth in MHB with (black
bars) or without (gray bars) 10 mM NAC.
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nosa. We do not presently have an appropriate explanation for
these discrepancies, although different variables, including pH,
bacterial inoculum, and growth broth, could be argued as being
responsible for the observed differences.
Apart from the indicated discrepancies, the main conclusion
from our results is that the presence of NAC resulted in a 16-fold
increase in the MIC of imipenem (from 1 to 16 g/ml), placing the
susceptible PAO1 strain clearly above the breakpoint for resis-
tance according to the clinical EUCAST breakpoints, v4.0 (http:
//www.eucast.org). The activity of meropenem is also affected,
though only slightly, by the NAC concentration used in this assay.
The effect of NAC on imipenem activity in P. aeruginosa is
mediated by OprD. Since the porin OprD facilitates the uptake of
imipenem and some amino acids in P. aeruginosa (14), we per-
formed a rapid double-disk synergy test to see if this porin is
involved in the NAC effect on imipenem activity. Figure 2 shows
that the antagonistic effect of NAC observed in the wild-type
(WT) strain P. aeruginosa PAO1 is drastically reduced in the oprD-
deficient strain, suggesting that OprD is mediating this phenom-
enon.
To gain insight into the involvement of OprD in the antago-
nistic effect of NAC on imipenem activity, we first quantitatively
evaluated the interactions between the drugs by the use of the
checkerboard method according to the EUCAST recommenda-
tions (19). For this assay, only the pharmaceutical formulation of
NAC (pH-independent effect) was used. The data shown in Fig.
3A demonstrate an antagonistic interaction between NAC and
imipenem in P. aeruginosa PAO1. The fractional inhibitory con-
centration index (FICi) (22) was 129. This value is 64 to 32 times
above the limit for antagonism, which has been suggested to be 2
TABLE 1 MICs of antibiotics in Mueller-Hinton broth containing different NAC preparations against P. aeruginosa PAO1 and P. aeruginosa PAO1
oprD-deficient derivative PAOD1
P. aeruginosa strain Antibiotic
MIC (g/ml) ina:
MH (pH 7.3) NAC-P (pH 7.2) NAC- (pH 5.7) NAC--pH (pH 7.2) NAC--EDTA-pH (pH 7.3)
PAO1 Ciprofloxacin 0.06 0.06 0.25 0.06 0.06
Tobramycin 0.25 0.25 8 0.25 0.25
Ceftazidime 1 1 2 1 1
Aztreonam 4 8 8 4 4
Imipenem 1 16 16 16 16
Meropenem 0.25 1 0.25 0.5 0.5
Colistin 0.5 0.5 1 0.5 0.5
PAO1 oprD Ciprofloxacin 0.06 0.06 0.25 0.06 0.125
Tobramycin 0.125 0.125 8 0.125 0.125
Ceftazidime 1 1 2 1 1
Aztreonam 4 8 8 4 4
Imipenem 16 32 16 32 32
Meropenem 2 8 2 4 4
Colistin 0.5 0.5 1 0.5 0.5
a The final pH of the broth is indicated. Values representing significant MIC modifications (4-fold) are in bold. In all cases, the concentration of NAC was adjusted to 10 mM (1.6
mg/ml). MH, only Mueller-Hinton broth; NAC-P, pharmaceutical preparation of NAC (Hidonac); NAC-, solution of NAC powder (Sigma) in water; NAC--pH, solution of
NAC powder in water where the pH was adjusted to 6.5 with sodium hydroxide; NAC--EDTA-pH, solution of NAC powder in water supplemented with edetate disodium (3 mg/
ml) as a preservative and sodium hydroxide (pH 6.5).
FIG 2 Antagonistic effect of NAC on imipenem activity. Different antagonistic effects of NAC on imipenem activity in P. aeruginosa PAO1 (WT) and its mutant
derivative PAO1 oprD were demonstrated by a double-disk synergy test. Disks of NAC (right) and IMI (left) contained 5 mg and 80 g, respectively. Note that
the distance between disks is shorter in the oprD plate. This is to show that an antagonism, although small, exists in the oprD mutant.
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or 4 (19, 22). Interestingly, a large effect on imipenem activity can
be observed at concentrations of NAC as low as 0.8 mg/ml (equiv-
alent to 5 mM), which are in the range of concentrations attain-
able in plasma after intravenous administration (23) or in lungs
after its administration via nebulization (21). However, the mean
plasma concentration of NAC after oral administration is far be-
low the concentration of NAC necessary to affect imipenem activ-
ity (24), even in patients with end-stage renal disease (25).
When the NAC/IMI antagonism was studied in the oprD mu-
tant derivative, the PAOD1 variant, the FICi value was 9 (Fig. 3B),
slightly over the cited antagonism limit. This result indicates that
more than 90% of the observed NAC effect is mediated by OprD.
We can conclude, therefore, that OprD is the principal factor in-
volved in the NAC-mediated decreased activity of imipenem in P.
aeruginosa, although another mechanism(s) may be additionally
involved in this effect.
It has been reported that some amino acids may negatively
regulate oprD transcription (26). Therefore, given that it is an
amino acid derivative, NAC could negatively regulate oprD tran-
scription, thus decreasing OprD production. To test this hypoth-
esis, we performed an analysis of OprD expression through SDS-
PAGE of outer membrane proteins (OMPs). As can be observed in
Fig. 4, the presence of NAC at 0.8 mg/ml or 1.6 mg/ml did not
modify the expression of OprD, ruling out this hypothesis.
Amino acids may also act as competitors of imipenem for
OprD (27, 28), competitively reducing the uptake of this carbap-
enem. Table 1 shows that the effect of NAC on the antibiotic
activities in the P. aeruginosa oprD-defective mutant PAOD1 is
similar to that in the wild-type strain PAO1, except for imipenem,
where only a marginal effect on the activity is produced. These
results also eliminate the possibility of the inhibition of imipenem
activity by a direct interaction with NAC. If this were the case, the
MIC of imipenem should have been increased in the oprD-defec-
tive mutant in a proportion similar to that observed in the
wild-type strain (i.e., about 16-fold). Therefore, our data
strongly suggest that the effect in P. aeruginosa is exerted mainly
via competition of NAC with imipenem by the OprD channel.
Obviously, this mechanism requires the simultaneous presence of
both compounds. Consequently, if NAC is eliminated (oxidized
or metabolized, for instance), bacterial cells should recover their
previous susceptibility to IMI. To test this hypothesis, cultures of
PAO1 and PAOD1 were incubated with 10 mM NAC for 2.5 h.
FIG 4 Effect of NAC on OprD expression. SDS-PAGE of outer membrane
proteins (OMPs) extracted from P. aeruginosa PAO1 and PAOD1 (oprD-de-
fective mutant) treated with NAC at 0.8 mg/ml and 1.6 mg/ml is shown. Con-
trols without NAC are also shown. The bands corresponding to OprD and
protein sizes of the molecular mass marker (in kDa) are shown.
TABLE 2 MICs of imipenem in Mueller-Hinton broth containing
different NAC preparations against different P. aeruginosa strains
Strain
MIC (g/ml) ina:
MH NAC-P NAC- NAC--pH NAC--EDTA-pH
PA14 0.5 16 2 8 4
Pamb18 2 32 16 32 16
Pamb91 2 16 8 16 8
FQSE21-1003 1 8 4 8 4
a Abbreviations and the final pH of the broth in each case are as described for Table 1.
Values representing significant MIC modifications (4-fold) are in bold. In all cases,
the concentration of NAC was adjusted to 10 mM (1.6 mg/ml).
FIG 3 Quantification of the effect of NAC on imipenem activity. The effect of combined treatment of NAC and imipenem on P. aeruginosa PAO1 (A) and
PAOD1 (B) as analyzed by the checkerboard method is shown. The solid line separates the wells in which the concentration of both drugs allowed growth (below
the line) from those with no growth (above). The dashed line indicates the expected effect if the combination of NAC and imipenem were exclusively additive.
The values of the fractional inhibitory concentration index (FICi) are shown.
N-Acetylcysteine Antagonizes Imipenem Activity
June 2015 Volume 59 Number 6 aac.asm.org 3249Antimicrobial Agents and Chemotherapy



























NAC was eliminated by saline washing, and the susceptibility to
IMI was compared to that of nonpretreated cultures. No differ-
ences were observed between the two conditions (data not
shown), indicating that the antagonistic effect is produced only
when both drugs are present simultaneously. This result rein-
forces the hypothesis that NAC directly competes with IMI by
OprD.
The NAC effect on imipenem activity is a general phenome-
non in P. aeruginosa. The generality of the NAC-modulating
effect on imipenem activity was tested on other P. aeruginosa
strains from different clinical origins, including cystic fibrosis and
bacteremia (14). Table 2 shows that imipenem activity is clearly
reduced for all these strains.
Effects of NAC on antibiotic activity in E. coli and A. bau-
mannii. The results with P. aeruginosa clearly demonstrate that is
the pH of the solution, not NAC by itself, which produces the
modulating effects on the activity of most antibiotics, with the
exception of imipenem. To analyze whether this is an exclusive
effect on P. aeruginosa, we performed identical studies with E. coli,
a species also used in the work of Goswami and Jawali (12), and A.
baumannii. Antibiotics currently used in the treatment of infec-
tions caused by these two species were tested.
Table 3 shows that, as for P. aeruginosa, the effect of NAC on
the activity of most antibiotics is fully attributable to the pH of the
solution in both E. coli and A. baumannii. Again, a clear pH-
independent effect on imipenem activity was observed in both
species. Meropenem activity is also slightly affected by NAC-P
when tested in E. coli but is not in A. baumannii. Interestingly, in
the latter species, the activities of the two last-resource antibiotics
used for the treatment of frequent multidrug-resistant strains,
colistin and tigecycline, were also affected by pH.
Conclusions. Our data show that the effect of NAC on the
activity of most antibiotics is due exclusively to the pH of the NAC
solution, and not to the NAC itself, in P. aeruginosa. It is already
known that factors such as divalent cation concentration, partial
pressure of oxygen, and pH can largely affect antibiotic activity
(29, 30). Particularly, an acidic pH compromises the activity of
aminoglycosides, quinolones, and erythromycin (31, 32).
Interestingly, the only activity clearly affected by NAC is that of
imipenem. This effect is independent of pH and is mediated
mainly by the OprD porin of P. aeruginosa. The main mechanism
underlying this effect in this species is likely the competitive inhi-
bition of imipenem uptake by the OprD channel, since the expres-
sion of OprD itself is not modified. Additional mechanisms of
inhibition cannot be ruled out, as the elimination of OprD does
not completely abolish the antagonistic NAC effect. The effect of
NAC on imipenem activity has been demonstrated for different P.
aeruginosa isolates. Finally, the generality of the pH-mediated
NAC effect has been demonstrated in two additional bacterial
species, E. coli and A. baumannii.
Although the clinical implications of the results presented here
remain to be confirmed, clinicians should take caution that the
susceptibility to imipenem determined in the microbiology labo-
ratory may be modified when this carbapenem is coadministered
with NAC, particularly in intravenous and nebulized regimes.
ACKNOWLEDGMENTS
We are grateful to Michael McConnell for useful scientific comments and
editing of the English in the manuscript.
This work was supported by the Ministerio de Ciencia e Innovación,
Instituto de Salud Carlos III, cofinanced by the European Development
Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the
Research in Infectious Diseases (REIPI RD12/0015), and FIS grant PI13/
00063. E.Y.V was funded by a postdoctoral fellowship from CNPq-Brazil
(CNPq 236914/2012-0).
REFERENCES
1. Aitio ML. 2006. N-acetylcysteine—passe-partout or much ado about
nothing? Br J Clin Pharmacol 61:5–15. http://dx.doi.org/10.1111/j.1365
-2125.2005.02523.x.
2. Samuni Y, Goldstein S, Dean OM, Berk M. 2013. The chemistry and
biological activities of N-acetylcysteine. Biochim Biophys Acta 1830:
4117– 4129. http://dx.doi.org/10.1016/j.bbagen.2013.04.016.
3. Mead GR, Woodhams AW. 1964. N-Acetyl-L-cysteine as liquefying agent
in the bacteriological examination of sputum. Tubercle 45:370 –373. http:
//dx.doi.org/10.1016/S0041-3879(64)80051-9.
4. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito
AM. 2003. Effect of fosfomycin alone and in combination with N-




MH NAC-P NAC- NAC--pH NAC--EDTA-pH
E. coli K-12 BW25113 Ciprofloxacin 0.008 0.008 0.25 0.008 0.015
Gentamicin 0.25 0.25 4 0.125 0.5
Tobramycin 0.5 0.5 8 0.5 0.5
Ampicillin 4 4 2 2 4
Ceftazidime 0.125 0.125 0.25 0.25 0.25
Imipenem 0.5 8 0.5 4 2
Meropenem 0.5 2 0.5 0.5 0.5
Colistin 0.5 0.5 0.5 0.5 0.5
A. baumannii ATCC 17978 Ciprofloxacin 0.125 0.125 1 0.125 0.125
Ceftazidime 8 16 16 16 16
Imipenem 0.5 8 2 8 8
Meropenem 0.25 0.25 0.125 0.25 0.25
Colistin 0.06 0.125 2 0.06 0.06
Tigecycline 0.015 0.015 1 0.015 0.015
a Abbreviations and the final pH of the broth in each case are as described for Table 1. Values representing significant MIC modifications (4-fold) are in bold.
Rodríguez-Beltrán et al.
3250 aac.asm.org June 2015 Volume 59 Number 6Antimicrobial Agents and Chemotherapy



























acetylcysteine on E. coli biofilms. Int J Antimicrob Agents 22(Suppl 2):
S95–S100. http://dx.doi.org/10.1016/S0924-8579(03)00232-2.
5. Zhao T, Liu Y. 2010. N-Acetylcysteine inhibit biofilms produced by
Pseudomonas aeruginosa. BMC Microbiol 10:140. http://dx.doi.org/10
.1186/1471-2180-10-140.
6. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ, Hurtado C, Blanco
MT, Gomez-Garcia AC. 1997. Influence of N-acetylcysteine on the for-
mation of biofilm by Staphylococcus epidermidis. J Antimicrob Che-
mother 39:643– 646. http://dx.doi.org/10.1093/jac/39.5.643.
7. Huynh HQ, Couper RT, Tran CD, Moore L, Kelso R, Butler RN. 2004.
N-acetylcysteine, a novel treatment for Helicobacter pylori infection. Dig
Dis Sci 49:1853–1861. http://dx.doi.org/10.1007/s10620-004-9583-2.
8. Rogers DF. 2007. Mucoactive agents for airway mucus hypersecretory
diseases. Respir Care 52:1176 –1193. (Discussion, 52:1193–1177.)
9. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F,
Iuliano L, Piroddi M, Dechecchi MC, Cabrini G, Working Group on
Inflammation in Cystic Fibrosis. 2012. Oxidative stress and antioxidant
therapy in cystic fibrosis. Biochim Biophys Acta 1822:690 –713. http://dx
.doi.org/10.1016/j.bbadis.2011.12.012.
10. Stafanger G, Koch C. 1989. N-Acetylcysteine in cystic fibrosis and Pseu-
domonas aeruginosa infection: clinical score, spirometry and ciliary mo-
tility. Eur Respir J 2:234 –237.
11. Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen PO, Johansen
HK, Qvist T, Kraemer D, Hoiby N, Ciofu O. 2015. The effect of short-
term, high-dose oral N-acetylcysteine treatment on oxidative stress mark-
ers in cystic fibrosis patients with chronic P. aeruginosa infection—a pilot
study. J Cyst Fibros 14:211–218. http://dx.doi.org/10.1016/j.jcf.2014.09
.015.
12. Goswami M, Jawali N. 2010. N-Acetylcysteine-mediated modulation of
bacterial antibiotic susceptibility. Antimicrob Agents Chemother 54:
3529 –3530. http://dx.doi.org/10.1128/AAC.00710-10.
13. Parry MF, Neu HC. 1977. Effect of N-acetylcysteine on antibiotic activity
and bacterial growth in vitro. J Clin Microbiol 5:58 – 61.
14. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a
new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant
Pseudomonas aeruginosa mutants selected in vitro and after antipseudomo-
nal treatment of intensive care unit patients. Antimicrob Agents Chemother
54:1213–1217. http://dx.doi.org/10.1128/AAC.01104-09.
15. Lopez-Causape C, Rojo-Molinero E, Mulet X, Cabot G, Moya B,
Figuerola J, Togores B, Perez JL, Oliver A. 2013. Clonal dissemination,
emergence of mutator lineages and antibiotic resistance evolution in Pseu-
domonas aeruginosa cystic fibrosis chronic lung infection. PLoS One
8:e71001. http://dx.doi.org/10.1371/journal.pone.0071001.
16. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya
B, Zamorano L, Suarez C, Pena C, Martinez-Martinez L, Oliver A. 2011.
Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa
isolates from bloodstream infections: prevalence and impact on resistance
in a Spanish multicenter study. Antimicrob Agents Chemother 55:1906 –
1911. http://dx.doi.org/10.1128/AAC.01645-10.
17. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko
KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia
coli K-12 in-frame, single-gene knockout mutants: the Keio collection.
Mol Syst Biol 2:2006.0008. http://dx.doi.org/10.1038/msb4100050.
18. Clinical and Laboratory Standards Institute. 2008. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed.
Approved standard M7-A7. CLSI, Wayne, PA.
19. European Committee for Antimicrobial Susceptibility Testing of the
European Society of Clinical Microbiology and Infectious Diseases.
2000. EUCAST definitive document E. Def 1.2, May 2000: terminology
relating to methods for the determination of susceptibility of bacteria to
antimicrobial agents. Clin Microbiol Infect 6:503–508. http://dx.doi.org
/10.1046/j.1469-0691.2000.00149.x.
20. Mushtaq S, Ge Y, Livermore DM. 2004. Doripenem versus Pseudomo-
nas aeruginosa in vitro: activity against characterized isolates, mutants,
and transconjugants and resistance selection potential. Antimicrob
Agents Chemother 48:3086 –3092. http://dx.doi.org/10.1128/AAC.48.8
.3086-3092.2004.
21. Szkudlarek U, Zdziechowski A, Witkowski K, Kasielski M, Luczynska
M, Luczynski R, Sarniak A, Nowak D. 2004. Effect of inhaled N-
acetylcysteine on hydrogen peroxide exhalation in healthy subjects. Pulm
Pharmacol Ther 17:155–162. http://dx.doi.org/10.1016/j.pupt.2004.01
.007.
22. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH.
2004. Combination antifungal therapy. Antimicrob Agents Chemother
48:693–715. http://dx.doi.org/10.1128/AAC.48.3.693-715.2004.
23. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. 1989. The dispo-
sition and kinetics of intravenous N-acetylcysteine in patients with parac-
etamol overdosage. Eur J Clin Pharmacol 37:501–506. http://dx.doi.org
/10.1007/BF00558131.
24. Lu C, Liu G, Jia J, Gui Y, Liu Y, Zhang M, Liu Y, Li S, Yu C. 2011. Liquid
chromatography tandem mass spectrometry method for determination of
N-acetylcysteine in human plasma using an isotope-labeled internal stan-
dard. Biomed Chromatogr 25:427– 431. http://dx.doi.org/10.1002/bmc
.1465.
25. Nolin TD, Ouseph R, Himmelfarb J, McMenamin ME, Ward RA. 2010.
Multiple-dose pharmacokinetics and pharmacodynamics of N-
acetylcysteine in patients with end-stage renal disease. Clin J Am Soc
Nephrol 5:1588 –1594. http://dx.doi.org/10.2215/CJN.00210110.
26. Ochs MM, McCusker MP, Bains M, Hancock RE. 1999. Negative reg-
ulation of the Pseudomonas aeruginosa outer membrane porin OprD
selective for imipenem and basic amino acids. Antimicrob Agents Che-
mother 43:1085–1090.
27. Trias J, Nikaido H. 1990. Outer membrane protein D2 catalyzes facili-
tated diffusion of carbapenems and penems through the outer membrane
of Pseudomonas aeruginosa. Antimicrob Agents Chemother 34:52–57.
http://dx.doi.org/10.1128/AAC.34.1.52.
28. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. 2012. Structure and
function of OprD protein in Pseudomonas aeruginosa: from antibiotic
resistance to novel therapies. Int J Med Microbiol 302:63– 68. http://dx
.doi.org/10.1016/j.ijmm.2011.10.001.
29. Blaser J, Luthy R. 1988. Comparative study on antagonistic effects of low
pH and cation supplementation on in-vitro activity of quinolones and
aminoglycosides against Pseudomonas aeruginosa. J Antimicrob Che-
mother 22:15–22. http://dx.doi.org/10.1093/jac/22.1.15.
30. Platt R, Rosner B. 1984. Effect of hydrogen ion and protein concentra-
tions on the activity of beta-lactam antibiotics. Rev Infect Diseases 6(Suppl
4):S829 –S834. http://dx.doi.org/10.1093/clinids/6.Supplement_4.S829.
31. Konig C, Simmen HP, Blaser J. 1993. Effect of pathological changes of pH,
pO2 and pCO2 on the activity of antimicrobial agents in vitro. Eur J Clin
Microbiol Infect Dis 12:519–526. http://dx.doi.org/10.1007/BF01970957.
32. Lorian V, Sabath LD. 1970. Effect of pH on the activity of erythromycin
against 500 isolates of gram-negative bacilli. Appl Microbiol 20:754 –756.
N-Acetylcysteine Antagonizes Imipenem Activity
June 2015 Volume 59 Number 6 aac.asm.org 3251Antimicrobial Agents and Chemotherapy
 on July 26, 2017 by IN
S
T
IT
U
T
O
 D
E
 P
A
R
A
S
IT
O
LO
G
F
A
 Y
http://aac.asm
.org/
D
ow
nloaded from
 
